Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the …

Do you trust this headline?

Based on recent headline ratings, 100% of this readership currently trusts the local media, which has an average score of 83% regionally and is currently trending positivepositive.


Media Trust Score100%